Christine Sadorge

507 total citations
15 papers, 356 citations indexed

About

Christine Sadorge is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Christine Sadorge has authored 15 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 7 papers in Microbiology and 6 papers in Infectious Diseases. Recurrent topics in Christine Sadorge's work include Bacterial Infections and Vaccines (6 papers), Herpesvirus Infections and Treatments (4 papers) and Pneumonia and Respiratory Infections (4 papers). Christine Sadorge is often cited by papers focused on Bacterial Infections and Vaccines (6 papers), Herpesvirus Infections and Treatments (4 papers) and Pneumonia and Respiratory Infections (4 papers). Christine Sadorge collaborates with scholars based in France, United Kingdom and Spain. Christine Sadorge's co-authors include Stéphane Thomas, Nathalie Jolly, Jean‐Baptiste Dufourcq, Nareth Chhor, Bernard Marcel Diop, Sivuth Ong, Laurent Dacheux, Dominique Rousset, Anne Fiquet and Philippe Buchy and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Urology and Vaccine.

In The Last Decade

Christine Sadorge

15 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christine Sadorge France 10 139 128 91 75 65 15 356
Charlotta Bergquist Sweden 8 201 1.4× 53 0.4× 94 1.0× 87 1.2× 258 4.0× 8 505
Larry Handt United States 7 147 1.1× 127 1.0× 124 1.4× 20 0.3× 102 1.6× 9 304
P. Massip France 11 129 0.9× 84 0.7× 165 1.8× 38 0.5× 45 0.7× 32 428
K. A. Dunn United Kingdom 8 168 1.2× 35 0.3× 113 1.2× 82 1.1× 26 0.4× 11 491
A H Balfour United Kingdom 15 434 3.1× 73 0.6× 93 1.0× 70 0.9× 54 0.8× 26 649
Christine Blondeau France 13 308 2.2× 174 1.4× 191 2.1× 171 2.3× 125 1.9× 20 606
Robin M. Kaufhold United States 11 418 3.0× 109 0.9× 74 0.8× 68 0.9× 159 2.4× 18 626
Gila Lustig South Africa 7 116 0.8× 58 0.5× 187 2.1× 132 1.8× 150 2.3× 12 462
Rafaela Giemza United Kingdom 8 161 1.2× 43 0.3× 216 2.4× 56 0.7× 242 3.7× 9 521
Fabien X. Lü United States 11 189 1.4× 259 2.0× 166 1.8× 49 0.7× 288 4.4× 11 577

Countries citing papers authored by Christine Sadorge

Since Specialization
Citations

This map shows the geographic impact of Christine Sadorge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Sadorge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Sadorge more than expected).

Fields of papers citing papers by Christine Sadorge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Sadorge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Sadorge. The network helps show where Christine Sadorge may publish in the future.

Co-authorship network of co-authors of Christine Sadorge

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Sadorge. A scholar is included among the top collaborators of Christine Sadorge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Sadorge. Christine Sadorge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Sadorge, Christine, Matthew D. Snape, Richard Tomlinson, et al.. (2020). Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine. 38(35). 5718–5725. 1 indexed citations
2.
3.
4.
Voysey, Merryn, Rama Kandasamy, Ly‐Mee Yu, et al.. (2016). The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. Vaccine. 34(35). 4221–4228. 8 indexed citations
5.
6.
Díez‐Domingo, Javier, Thomas Weinke, Juan García de Lomas, et al.. (2014). Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial. Vaccine. 33(6). 789–795. 32 indexed citations
7.
Vesikari, Timo, Roland Hardt, H. C. Rümke, et al.. (2013). Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines & Immunotherapeutics. 9(4). 858–864. 28 indexed citations
8.
Díez‐Domingo, Javier, et al.. (2013). A clinical study of a shingles (Herpes Zoster) vaccine (Live) administered by intramuscular or subcutaneous routes in adults aged≥50 years. European Geriatric Medicine. 4. S117–S117. 3 indexed citations
9.
Laurichesse, H., U. Zimmermann, Florence Galtier, et al.. (2012). Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults. Human Vaccines & Immunotherapeutics. 8(12). 1875–1881. 2 indexed citations
10.
Fiquet, Anne, et al.. (2011). Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years. Human Vaccines. 7(10). 1060–1065. 12 indexed citations
11.
12.
Bisiaux, Aurélie, Nicolas Thiounn, Marc‐Olivier Timsit, et al.. (2009). Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer. The Journal of Urology. 181(4). 1571–1580. 70 indexed citations
13.
14.
Dacheux, Laurent, Jean‐Marc Reynes, Philippe Buchy, et al.. (2008). A Reliable Diagnosis of Human Rabies Based on Analysis of Skin Biopsy Specimens. Clinical Infectious Diseases. 47(11). 1410–1417. 114 indexed citations
15.
Sadorge, Christine, Anna Julienne Selbé Ndiaye, Rafaela Giemza, et al.. (2007). Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 ΔicsA Δent Δfep ΔstxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine. 26(7). 978–987. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotta Bergquist Breakdown of academic impact, for papers by Larry Handt Breakdown of academic impact, for papers by P. Massip Breakdown of academic impact, for papers by K. A. Dunn Breakdown of academic impact, for papers by A H Balfour Breakdown of academic impact, for papers by Christine Blondeau Breakdown of academic impact, for papers by Robin M. Kaufhold Breakdown of academic impact, for papers by Gila Lustig Breakdown of academic impact, for papers by Rafaela Giemza Breakdown of academic impact, for papers by Fabien X. Lü
Rankless by CCL
2026